Iminem (500 mg+500 mg)/vial (IV Injection)

Indications

• Lower respiratory tract infections
• Urinary tract infections
• Intra-abdominal infections
• Gynecologic infections
• Bacterial septicemia
• Bone and joint infections
• Skin and skin structure infections
• Endocarditis

Pharmacology

Imipenem is a penem antibacterial drug with bactericidal activity resulting from the inhibition of cell wall synthesis. Cilastatin sodium is a renal dehydropeptidase inhibitor that limits the renal metabolism of imipenem.

Dosage & Administration

• Adult Patients:
  • Dosage based on suspected or confirmed pathogen susceptibility
  • Recommended dosage regimens: 500 mg every 6 hours, 1000 mg every 8 hours, 1000 mg every 6 hours
  • Dose reduction for patients with creatinine clearance of less than 90 mL/min
  • Patients with creatinine clearances of less than 15 mL/min should not receive this combination unless hemodialysis is instituted within 48 hours
• Pediatric Patients for Non-CNS Infections:
  • Greater than or equal to 3 Months of Age: 15-25 mg/kg in every 6 hours
  • Less than or equal to 3 months of age: 4 weeks to 3 months of age: 25 mg/kg in every 6 hours, 1 to 4 weeks of age: 25 mg/kg in every 8 hours, Less than 1 week of age: 25 mg/kg in every 12 hours
• Administration Method: Reconstitute with appropriate diluent and dilute the suspension with an appropriate infusion solution before administering by intravenous infusion

Interaction

• Concurrent admin with probenecid may increase the half-life of cilastatin
• Increased risk of generalized seizures when used concurrently with ganciclovir

Contraindications

Hypersensitivity to any component of this combination

Side Effects

• Phlebitis
• Nausea, diarrhea, vomiting
• Rash, pruritus, urticaria
• Pain at injection site, erythema at injection site, vein induration
• Fever
• Hypotension
• Seizures, dizziness, somnolence

Pregnancy & Lactation

• Pregnancy Category: C
• Usage in Pregnancy: Should be used during pregnancy only if the potential benefit justifies the potential risk to the mother and fetus
• Usage in Lactation: Caution should be exercised when administered to a nursing woman

Precautions & Warnings

• Hypersensitivity Reactions: Serious and occasionally fatal hypersensitivity (anaphylactic) reactions have been reported in patients receiving therapy with beta-lactams. Discontinue the drug immediately if an allergic reaction occurs
• Seizure Potential: Seizures and other CNS adverse reactions have been reported during treatment with this combination

Therapeutic Class

Other beta-lactam Antibiotics

Reconstitution

• Reconstitution and Preparation:
  • Do not use diluents containing benzyl alcohol to reconstitute for administration to neonates
  • Contents of the vials must be reconstituted by adding approximately 10 mL of 0.9% Sodium Chloride Injection
  • The reconstituted suspension must not be administered by direct Intravenous Infusion
  • Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration
• Storage of Reconstituted Solutions: Satisfactory potency for 4 hours at room temperature or for 24 hours under refrigeration (5°C)

Storage Conditions

Store at or below 25°C temperature. Keep away from light and wet place. Keep out of reach of children

Related Brands

• Imbac (500 mg+500 mg)/vial (IV Injection) - popular-pharmaceuticals-ltd
• Cispenam (500 mg+500 mg)/vial (IV Injection) - incepta-pharmaceuticals-ltd